Form D · Biotechnology
Vita Therapeutics, Inc.
Baltimore, MD · CIK 0001843252
Offering snapshot reported Oct 20, 2022 · SEC filing
- Reported sold
- $30.9M Offering amount: $30.9M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 11, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 20, 2022 | Initial | $30,892,998 | No comparison | 7 | SEC filing |
| Nov 30, 2021 | Initial | $11,999,992 | No comparison | 15 | SEC filing |
| Jan 29, 2021 | Initial | $20,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-462316
Source: Form D, filed Oct 20, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Faizzan Ahmad | Director |
| Eva Chin | Director |
| David Churchill | Director |
| Vlad Coric | Director |
| Douglas Falk | Director, Executive |
| Pat La Vecchia | Director |
| Mark Nuttall | Director |
| James Peyer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
801 W. Baltimore Street Suite 301
Baltimore, MD, 21201
Baltimore, MD, 21201